Maiwei Biomedical (688062.SH) disclosed its semi-annual report for the year 2024, with the company achieving revenues of 1.16... during the reporting period.
According to the semi-annual report for the year 2024 released by Maiwei Biomedical (688062.SH), the company achieved revenues of 0.116 billion yuan, with a year-on-year growth of 28.42%. The net income attributable to shareholders increased to a loss of 0.445 billion yuan compared to the same period last year, with a year-on-year expansion. The non-GAAP net income also increased to a loss of 0.461 billion yuan, with a year-on-year expansion. The basic earnings per share is -1.11 yuan.
